Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome– a single center experience

BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) can result in severe kidney dysfunction, secondary to thrombotic microangiopathy. Eculizumab has been used to treat this disorder, and has resulted in favourable outcomes in both, native and transplanted kidneys. There is limited long term follow...

Descripción completa

Detalles Bibliográficos
Autores principales: Kant, Sam, Bhalla, Anshul, Alasfar, Sami, Alachkar, Nada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238522/
https://www.ncbi.nlm.nih.gov/pubmed/32434487
http://dx.doi.org/10.1186/s12882-020-01847-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238522/
https://www.ncbi.nlm.nih.gov/pubmed/32434487
http://dx.doi.org/10.1186/s12882-020-01847-0

Ejemplares similares